- Home
- TENX vs PASG Comparison
TENX vs PASG Comparison
Compare TENX & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TENX
- PASG
- Stock Information
- Founded
- TENX 1967
- PASG 2017
- Country
- TENX United States
- PASG United States
- Employees
- TENX N/A
- PASG N/A
- Industry
- TENX Biotechnology: Pharmaceutical Preparations
- PASG Biotechnology: Pharmaceutical Preparations
- Sector
- TENX Health Care
- PASG Health Care
- Exchange
- TENX Nasdaq
- PASG Nasdaq
- Market Cap
- TENX 27.3M
- PASG 25.9M
- IPO Year
- TENX N/A
- PASG 2020
- Fundamental
- Price
- TENX $7.79
- PASG N/A
- Analyst Decision
- TENX Strong Buy
- PASG Strong Buy
- Analyst Count
- TENX 4
- PASG 4
- Target Price
- TENX $16.67
- PASG $59.25
- AVG Volume (30 Days)
- TENX 119.0K
- PASG 41.2K
- Earning Date
- TENX 11-12-2025
- PASG 11-12-2025
- Dividend Yield
- TENX N/A
- PASG N/A
- EPS Growth
- TENX N/A
- PASG N/A
- EPS
- TENX N/A
- PASG N/A
- Revenue
- TENX N/A
- PASG N/A
- Revenue This Year
- TENX N/A
- PASG N/A
- Revenue Next Year
- TENX N/A
- PASG N/A
- P/E Ratio
- TENX N/A
- PASG N/A
- Revenue Growth
- TENX N/A
- PASG N/A
- 52 Week Low
- TENX $3.25
- PASG $5.12
- 52 Week High
- TENX $7.98
- PASG $26.60
- Technical
- Relative Strength Index (RSI)
- TENX 77.22
- PASG 61.20
- Support Level
- TENX $7.45
- PASG $7.84
- Resistance Level
- TENX $7.82
- PASG $8.20
- Average True Range (ATR)
- TENX 0.31
- PASG 0.37
- MACD
- TENX 0.06
- PASG -0.02
- Stochastic Oscillator
- TENX 84.50
- PASG 55.41
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.